[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE60304726D1 - Benzimidazolderivative und ihre verwendung als prodrugs für protonenpumpenhemmer - Google Patents

Benzimidazolderivative und ihre verwendung als prodrugs für protonenpumpenhemmer

Info

Publication number
DE60304726D1
DE60304726D1 DE60304726T DE60304726T DE60304726D1 DE 60304726 D1 DE60304726 D1 DE 60304726D1 DE 60304726 T DE60304726 T DE 60304726T DE 60304726 T DE60304726 T DE 60304726T DE 60304726 D1 DE60304726 D1 DE 60304726D1
Authority
DE
Germany
Prior art keywords
prodrugs
pump inhibitors
protonal
benzimidazole derivatives
bioavailability
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60304726T
Other languages
English (en)
Other versions
DE60304726T2 (de
Inventor
Michael E Garst
George Sachs
Jai Moo Shin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Winston Pharmaceuticals LLC
US Department of Veterans Affairs VA
Original Assignee
University of California
Winston Pharmaceuticals LLC
US Department of Veterans Affairs VA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, Winston Pharmaceuticals LLC, US Department of Veterans Affairs VA filed Critical University of California
Publication of DE60304726D1 publication Critical patent/DE60304726D1/de
Application granted granted Critical
Publication of DE60304726T2 publication Critical patent/DE60304726T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
DE60304726T 2002-07-19 2003-07-15 Benzimidazolderivative und ihre verwendung als prodrugs für protonenpumpenhemmer Expired - Lifetime DE60304726T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39745902P 2002-07-19 2002-07-19
US397459P 2002-07-19
PCT/US2003/022419 WO2004009583A2 (en) 2002-07-19 2003-07-15 Benzimidazole derivatives and their use as prodrugs of proton pump inhibitor

Publications (2)

Publication Number Publication Date
DE60304726D1 true DE60304726D1 (de) 2006-05-24
DE60304726T2 DE60304726T2 (de) 2007-08-09

Family

ID=30771064

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60304726T Expired - Lifetime DE60304726T2 (de) 2002-07-19 2003-07-15 Benzimidazolderivative und ihre verwendung als prodrugs für protonenpumpenhemmer

Country Status (23)

Country Link
US (3) US6897227B2 (de)
EP (1) EP1556371B1 (de)
JP (1) JP4463103B2 (de)
KR (2) KR100788778B1 (de)
AT (1) ATE323695T1 (de)
AU (1) AU2003259154B2 (de)
BR (1) BR0312802A (de)
CA (1) CA2492718C (de)
CO (1) CO5690576A2 (de)
DE (1) DE60304726T2 (de)
DK (1) DK1556371T3 (de)
ES (1) ES2263028T3 (de)
HK (1) HK1079207A1 (de)
IL (1) IL166371A0 (de)
MX (1) MXPA05000657A (de)
NO (1) NO20050801L (de)
NZ (1) NZ538221A (de)
PL (1) PL375255A1 (de)
PT (1) PT1556371E (de)
RU (1) RU2292342C2 (de)
TW (1) TW200502231A (de)
WO (1) WO2004009583A2 (de)
ZA (1) ZA200501116B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852739B1 (en) * 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
CA2493618A1 (en) * 2002-08-01 2004-02-12 Nitromed, Inc. Nitrosated proton pump inhibitors, compositions and methods of use
CN1823058A (zh) * 2003-07-15 2006-08-23 阿勒根公司 制备质子泵抑制剂的异构纯前体药物的方法
US20060241037A1 (en) * 2003-10-03 2006-10-26 Allergan Inc. Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump ihhibitor prodrugs
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
BRPI0507837A (pt) * 2004-02-18 2007-07-10 Allergan Inc métodos e composições para a administração intravenosa de compostos relacionados a inibidores de bomba de prótons
EP1715861A2 (de) * 2004-02-18 2006-11-02 Allergan, Inc. Prodrugs von protonenpumpinhibitoren enthaltende zusammensetzungen
AU2005222574A1 (en) * 2004-03-11 2005-09-29 Allergan, Inc. Methods and compositions for the treatment of conditions related to gastric acid secretion
DK1740571T3 (da) 2004-04-28 2009-11-02 Hetero Drugs Ltd Fremgangsmåde til fremstilling af pyridinylmethyl-1H-benzimidazolforbindelser i enantiomerisk beriget form eller som enkelte enantiomerer
WO2007073301A1 (en) * 2005-12-23 2007-06-28 Astrazeneca Ab Benzoimidazole derivatives as prodrugs of proton pump inhibitors
US20070265311A1 (en) * 2006-01-10 2007-11-15 Rubino Mark P Therapeutic Salt Compositions and Methods
NZ572007A (en) * 2006-05-09 2010-12-24 Astrazeneca Ab Parenteral formulation comprising proton pump inhibitor sterilized in its final container by ionizing radiation
US20070293543A1 (en) * 2006-06-19 2007-12-20 Edward Lee THRESHOLD BLOOD OMEPRAZOLE CONCENTRATION IS 50 NG/ML FOR THE MAINTENANCE OF INTRAGASTRIC pH OF AT LEAST 4.0 AFTER ORAL DOSING WITH CMA-OMEPRAZOLE, AGN 201904-Z
WO2008036211A1 (en) * 2006-09-19 2008-03-27 Alevium Pharmaceuticals, Inc. Prodrugs of proton pump inhibitors including the (1h-pyrrol-1-yl)-1h-benzimidazole moiety
WO2008036201A1 (en) * 2006-09-19 2008-03-27 Alevium Pharmaceuticals, Inc. Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety
KR20090035195A (ko) * 2007-10-05 2009-04-09 엘지전자 주식회사 플라즈마 디스플레이 장치
EP2193518A4 (de) * 2007-10-05 2010-10-27 Lg Electronics Inc Plasmaanzeigevorrichtung
KR100895333B1 (ko) * 2007-11-01 2009-05-07 엘지전자 주식회사 플라즈마 디스플레이 패널의 구동 방법 및 그를 이용한플라즈마 디스플레이 장치
US8927559B2 (en) 2010-10-11 2015-01-06 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as CRTH2 antagonists
WO2012087872A1 (en) 2010-12-23 2012-06-28 Merck Sharp & Dohme Corp. Quinolines and aza-quinolines as crth2 receptor modulators
MX2013007295A (es) 2010-12-23 2013-08-26 Merck Sharp & Dohme Quinoxalinas y aza-quinoxalinas como moduladores del receptor de crth2.
US20180021319A1 (en) * 2015-01-09 2018-01-25 The Regents Of The University Of California Compositions and methods for treating gastrointestinal infections
CN108997177A (zh) * 2018-09-04 2018-12-14 邵阳学院 一种微波促进n-苯磺酰基硝基苯胺类化合物合成的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US430042A (en) * 1890-06-10 Valve
SE416649B (sv) * 1974-05-16 1981-01-26 Haessle Ab Forfarande for framstellning av foreningar som paverkar magsyrasekretionen
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
JPS6150978A (ja) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
IL76839A (en) * 1984-10-31 1988-08-31 Byk Gulden Lomberg Chem Fab Picoline derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
SE8505112D0 (sv) * 1985-10-29 1985-10-29 Haessle Ab Novel pharmacological compounds
US4758597A (en) * 1987-05-15 1988-07-19 University Patents, Inc. Carenadiol and derivatives
US4965269A (en) * 1989-12-20 1990-10-23 Ab Hassle Therapeutically active chloro substituted benzimidazoles
US5045522A (en) * 1990-03-27 1991-09-03 Phillips Petroleum Company Absorption composition comprising zinc titanate for removal of hydrogen sulfide from fluid streams
ATE184602T1 (de) * 1990-06-20 1999-10-15 Astra Ab Dialkoxypyridinylbenzimidazolderivate, verfahren zur herstellung und ihre pharmazeutische verwendung
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
HU220062B (hu) * 1994-06-10 2001-10-28 Byk Gulden Lomberg Chemische Fabrik Gmbh Helyettesített alkil-tio-piridinil-metil-tio-benzimidazol és -imidazo[4,5-b]piridin-származékok és felhasználásuk gyógyszerkészítmények előállítására
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
US6093734A (en) * 1998-08-10 2000-07-25 Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin Prodrugs of proton pump inhibitors
MXPA01001464A (es) * 1998-08-10 2002-05-08 Partnership Of Michael E Garst Precursores de inhibidores de la bomba de protones.
MXPA01001552A (es) * 1998-08-12 2004-08-23 Triangle Pharmaceuticals Inc Metodo de elaboracion de 1,3-oxatiolan-nucleosidos.
SE0002476D0 (sv) 2000-06-30 2000-06-30 Astrazeneca Ab New compounds
US6599167B2 (en) * 2000-09-27 2003-07-29 Glenn Waltz Game call holder and amplifying device
AU2001294228A1 (en) * 2000-10-12 2002-04-22 Takeda Chemical Industries Ltd. Benzimidazole compounds, process for producing the same and use thereof

Also Published As

Publication number Publication date
AU2003259154B2 (en) 2006-12-07
JP2005536519A (ja) 2005-12-02
CO5690576A2 (es) 2006-10-31
US20050143423A1 (en) 2005-06-30
AU2003259154C1 (en) 2004-02-09
EP1556371A2 (de) 2005-07-27
RU2005105564A (ru) 2005-10-10
PT1556371E (pt) 2006-09-29
WO2004009583A3 (en) 2004-03-18
JP4463103B2 (ja) 2010-05-12
HK1079207A1 (en) 2006-03-31
CA2492718A1 (en) 2004-01-29
AU2003259154A1 (en) 2004-02-09
KR100822981B1 (ko) 2008-04-16
RU2292342C2 (ru) 2007-01-27
DK1556371T3 (da) 2006-08-21
IL166371A0 (en) 2006-01-16
BR0312802A (pt) 2005-04-19
EP1556371B1 (de) 2006-04-19
NO20050801L (no) 2005-02-15
ATE323695T1 (de) 2006-05-15
ZA200501116B (en) 2006-11-29
KR20070005029A (ko) 2007-01-09
ES2263028T3 (es) 2006-12-01
PL375255A1 (en) 2005-11-28
TW200502231A (en) 2005-01-16
KR100788778B1 (ko) 2007-12-27
MXPA05000657A (es) 2005-08-19
DE60304726T2 (de) 2007-08-09
WO2004009583A2 (en) 2004-01-29
US20040102484A1 (en) 2004-05-27
US20050182101A1 (en) 2005-08-18
KR20050047078A (ko) 2005-05-19
NZ538221A (en) 2006-11-30
CA2492718C (en) 2010-12-21
US6897227B2 (en) 2005-05-24

Similar Documents

Publication Publication Date Title
DE60304726D1 (de) Benzimidazolderivative und ihre verwendung als prodrugs für protonenpumpenhemmer
DE602006016313D1 (de) Biphenylderivate und ihre verwendung bei der behandlung von hepatitis c
ATE495176T1 (de) Spiroindolinon-derivate
NO20025590D0 (no) Fenylglycin-derivater
MXPA05010000A (es) Derivados de p-diaminobenceno substituidos.
NO20062699L (no) Smelteblandingsdispergeringer
EA200801200A1 (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛИЗОХИНОЛИНМОЧЕВИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ p38 КИНАЗЫ
ATE303384T1 (de) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
DE60313350D1 (de) Pyrimidin-2,4-dion-derivate als matrix-metalloproteinase-hemmer
BRPI0516981A (pt) inibidores de mif
CO5700775A2 (es) Nuevos derivados triciclicos como antagonistas de ltd4
MXPA05009282A (es) Derivados de anilina sustituidos.
ATE355265T1 (de) Biphenylcarboxamidderivate und ihre verwendung als p38 kinase inhibitoren
ATE465151T1 (de) 4-aryloxy-chinolin-derivate als 5-ht6-modulatoren
ATE373637T1 (de) N-(2-phenylethyl)sulfamid-derivate als integrin- alpha4-antagonisten
SG171472A1 (en) Substituted aniline derivatives
ATE256124T1 (de) Substituierte benzimidazole, ihre herstellung und ihre verwendung als mittel gegen parasitäre protozoen
ATE296295T1 (de) Polycyclische thiazol-systeme und ihre verwendung als anorektika
ATE277591T1 (de) Verwendung von n,n'- dibenzylethylendiamindiessigsäurederivaten zum schutz gegen verschmutzung
DE60009032T2 (de) Benzolsulfonamid-derivate und ihre verwendung
DE602004019939D1 (de) Thiazolderivate als npy-antagonisten
ATE236887T1 (de) Arylsulfonamid-substituierte benzimidazolderivate und ihre verwendung als tryptase-inhibitoren
BR0317126A (pt) Derivados de indol e o uso dos mesmos como ligantes de 5-ht
DE50003307D1 (de) Arylsulfonamid-substituierte benzimidazolderivate ihre verwendung als tryptase-inhibitoren
IS8034A (is) Imídasó[4,5-B]kínólínafleiður og notkun þeirra sem NO-myndunarhemla

Legal Events

Date Code Title Description
8364 No opposition during term of opposition